Beigene, Ltd. ((ONC)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Beigene, Ltd. is conducting a Phase 2/3 clinical study to evaluate the efficacy and safety of zanubrutinib in adults with primary membranous nephropathy (PMN). This study aims to assess proteinuria reduction and compare zanubrutinib’s efficacy with tacrolimus in achieving complete remission in patients receiving optimal supportive care.
The study tests zanubrutinib, an oral drug administered in high and low doses, against tacrolimus, an existing treatment. Zanubrutinib is intended to improve outcomes for PMN patients by reducing proteinuria and achieving remission.
This interventional study is randomized with a parallel assignment model and no masking, focusing on treatment as the primary purpose. Participants are divided into groups receiving either zanubrutinib or tacrolimus.
The study began on April 17, 2023, with primary completion and estimated completion dates set for June 23, 2025. These dates are crucial for tracking progress and anticipating results that could influence market dynamics.
The study’s progress could impact Beigene’s stock performance positively if results show zanubrutinib’s superiority or comparable efficacy to tacrolimus. This could enhance investor sentiment and position Beigene favorably against competitors in the nephropathy treatment market.
The study is ongoing, with updates available on the ClinicalTrials portal.